Journals / Viral Hepatitis Journal / 2021 / Cilt: 27 - Sayı: 1

Seroprevalence of HBsAg and Anti-HCV among HIV Positive Patients

HIV Enfeksiyonu Olan Bireylerde HBsAg ve Anti-HCV Seroprevlansının Araştırılması

Pages
24–30
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The prevalence of HIV/ HCV coinfection was statistically significantly higher in intravenous (IV) drug users than HIV-monoinfected patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The study aimed to investigate the seroprevalence of hepatitis B surface antigen (HBsAg) and hepatitis C virus (anti- HCV) in human immunodeficiency virus (HIV) infected patients and to evaluate the results according to risk factors in our hospital in İstanbul, which was one of the centers where HIV-infected patients were followed up the most in our country.
📊
Key Findings & Data:Materials and Methods: The medical files of 611 HIV-infected patients who were followed up in our infectious diseases and clinical microbiology outpatient clinic between 1999 and 2016, were analyzed to determine the seroprevalence of HBsAg and anti-HCV retrospectively.
💡
Conclusion & Impact:The prevalence of HIV/ HCV coinfection was statistically significantly higher in intravenous (IV) drug users than HIV-monoinfected patients (p
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The study aimed to investigate the seroprevalence of hepatitis B surface antigen (HBsAg) and hepatitis C virus (anti- HCV) in human immunodeficiency virus (HIV) infected patients and to evaluate the results according to risk factors in our hospital in İstanbul, which was one of the centers where HIV-infected patients were followed up the most in our country. Materials and Methods: The medical files of 611 HIV-infected patients who were followed up in our infectious diseases and clinical microbiology outpatient clinic between 1999 and 2016, were analyzed to determine the seroprevalence of HBsAg and anti-HCV retrospectively. HIV-monoinfected patients, HIV+HBV-coinfected patients, and HIV+HCV-coinfected patients were examined separately in terms of demographic characteristics and risk factors, and compared with each other. Results: Of the patients 86.6% were male. The mean age of the patients was 37.0±11.2 (16-83). More than one-third of patients were 30-39 years old. Of the patients 43.7% were men who had sex with men (MSM). Of the patients, 5.8% were HBsAg-positive and 14.7% (236) of patients were positive for isolated anti-HBc IgG. The HBV-DNA positivity ratio was determined as 8.7% in the isolated anti-HBc IgG positive group. Of the patients 2% were anti-HCV positive, and 0.9% were HCV-RNA positive. The prevalence of HIV/ HCV coinfection was statistically significantly higher in intravenous (IV) drug users than HIV-monoinfected patients (p

Özet

Amaç: Çalışmamızda, ülkemizde en çok HIV enfekte hasta takibi yapılan merkezlerden biri olan İstanbul’daki hastanemizde, insan bağışıklık yetmezliği virüsü (HIV) enfekte bireylerde hepatit B yüzey antijen (HBsAg) ve anti-HCV seroprevalansının araştırılması ve risk faktörlerine göre değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Mart 1999-Mart 2016 yılları arasında enfeksiyon hastalıkları ve klinik mikrobiyoloji polikliniğimizde takip edilen HIV/AIDS hastalarının dosyalarında kayıtlı olan veriler retrospektif olarak incelenerek HBsAg ve anti-HCV seroprevalansı araştırılmıştır. HIV ile monoenfekte, HIV/HBV koenfekte ve HIV/HCV koenfekte hastalar; demografik özellikleri ve risk faktörleri açısından ayrı ayrı incelenmiş ve birbiri ile kıyaslanmıştır. Bulgular: Çalışmaya alınan 611 hastanın 529’u (%86,6) erkek idi. Hastaların yaş ortalaması 37,0±11,2 (16-83) olup 1/3’ünden fazlası 30-39 yaş arasında saptanmıştır. Hastaların 236’sında (%43,7) erkek homoseksüel temas öyküsü vardır. Hastaların %5,8’inde HBsAg pozitifliği, %14,7’sinde izole anti-hepatit B çekirdek antijen immünoglobulin (anti-HBc IgG) pozitifliği tespit edilmiştir. İzole anti-HBc IgG pozitif bulunanlarda HBV-DNA pozitifliği %8,7 olarak saptanmıştır. Hastaların 11’inde (%2) anti-HCV pozitif iken 5’inde (%0,9) HCV-RNA pozitif bulunmuştur. Damar içi uyuşturucu madde kullananlarda HIV/HCV koenfeksiyonu, HIV monoenfekte hastalara kıyasla istatistiksel olarak anlamlı düzeyde yüksek saptanmıştır (p

🔖

Cite This Article

Aydın, Ö. A., Karaosmanoğlu, H. K., Şahin, M., Yıldırım, M. (2022). Seroprevalence of HBsAg and Anti-HCV among HIV Positive Patients. Viral Hepatitis Journal, Cilt: 27 - Sayı: 1, 24–30. https://ajindex.com/articles/646315

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Noubiap JJ, Aka PV, Nanfack AJ, Agyingi LA, Ngai JN, Nyambi PN. Hepatitis B and C co-infections in some HIV positive populations in Cameroon, West Central Africa: analysis of samples collected over more than a decade. PLoS One. 2015;10:e0137375
  2. Gunduz A. HIV coinfections. (hepatitis B virus, hepatitis C virus). Turkiye Klinikleri J Inf Dis-Special Topics. 2016;9:79-86
  3. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection a global challenge. N Engl J Med. 2012;366:1749-1752
  4. World Health Organization Europe [Internet]. Copenhagen: The Association; c1948-2020 [cited 2020 Marc 03]. Management hepatitis B and HIV coinfection; Clinical Protocol for the WHO European Region (2011 Revision) [about 2 screens]. Available from:
  5. Boesecke C, Wasmuth JC, Rockstroh JK. HIV and HBV/HCV coinfections. In: Hoffmann C, Rockstroh JK (eds.), HIV 2015/16 www.hivbook.com. Hamburg: Medizin Fokus Verlag; 2015. p. 454-466
  6. Aydın OA. HIV/HCV koenfeksiyonu. Tabak F, Tosun S, (eds.), Viral Hepatit 2013, Viral Hepatit Savaşım Derneği. Istanbul: Istanbul Tıp Kitapevi; 2013. p. 547-552
  7. Petty LA, Steinbeck JL, Pursell K, Jensen DM. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014;28:477-499
  8. Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM. Hepatitis B and C coinfection in HIV patients from the TREAT Asia HIV observational database: analysis of risk factors and survival. PLoS One 2016;11:e0150512
  9. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212- 2219
  10. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD; EuroSIDA Group. Hepatitis B and HIV: Prevalence, AIDS progression, response to Highly Active Antiretroviral Therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593-601
  11. Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA. Prevalence of hepatitis B and C viral coinfection among HIV-1 infected individuals in Nairobi, Kenya. BMC Res Notes. 2013;6:363
  12. Zago AM, Machado TF, Cazarim FL, Miranda AE. Prevalence and r